Adicet Bio, Inc. — Director's Dealing 2022

Aug 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adicet Bio, Inc. (ACET)
CIK: 0001720580
Period of Report: 2022-08-04

Reporting Person: Schor Chen (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-06	Common Stock	G	53424	$0.00	Disposed	96000	Direct
2022-07-06	Common Stock	G	53424	$0.00	Acquired	143260	Indirect
2022-08-04	Common Stock	A	48000	$0.00	Acquired	144000	Direct
2022-08-04	Common Stock	F	21288	$18.25	Disposed	122712	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	74841	Indirect

Footnotes

F1: Represents the transfer of shares held by the Reporting Person to The C. Schor IRRV Trust for no consideration.

F2: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

F3: The Reporting Person was issued 240,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 96,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 144,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Person's Restricted Stock Unit Agreement. On August 4, 2022, upon the occurrence of the third performance milestone, 48,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

F4: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee.